This document summarizes the pharmacotherapy of depression. It discusses the major classifications of antidepressants including SSRIs, SNRIs, TCAs, and others. It covers the pathophysiology of depression including the monoamine and neurotrophic hypotheses. For each class of antidepressant, it describes the pharmacokinetics, pharmacodynamics, dosing ranges, adverse effects, and drug interactions. CYP enzyme metabolism is an important factor in antidepressant interactions. The document provides a comprehensive overview of antidepressant treatment of depression and other conditions.
Similar to Pharmacotherapy of Depression: A Guide to Antidepressant Classification, Mechanisms of Action, Pharmacokinetics, Clinical Use, and Drug Interactions
Similar to Pharmacotherapy of Depression: A Guide to Antidepressant Classification, Mechanisms of Action, Pharmacokinetics, Clinical Use, and Drug Interactions (20)
2. Contents
• Introduction
• Pathophysiology
• Classification of antidepressants
• Pharmacokinetics and pharmacodynamics
• Adverse effects and drug interactions
• CYP enzymes and antidepressants
3. MAJOR DEPRESSIVE DISORDER
• SAD MOOD
• LOSS OF INTEREST
• LOW ENERGY
• GUILT
• PSYCHOMOTOR RETARDATION
• SUICIDAL THOUGHTS
• MELANCHOLIA
4. Pathophysiology of Major Depression
• Monoamine hypothesis
• Neurotrophic hypothesis
• Neuroendocrine Factors
5. Neurotrophic hypothesis
Brain-derived neurotrophic factor (BDNF)
- neural plasticity
- resilience
- neurogenesis
Tyrosine kinase receptor B in both neurons and glia
BDNF - atrophic changes in hippocampus , medial frontal cortex and
anterior cingulate
6.
7. Monoamine hypothesis
Deficiency - nor-adrenaline (NE) and dopamine (DA) and serotonin(5ht) in the
CNS
Evidence – Reserpine, which has antihypertensive actions due to its
ability to deplete catecholamines (DA and NE) and 5HT from peripheral
sympathetic nerve endings, caused depression
Drugs that promote catecholamines and serotonin in the synapse relieved
depression
– MAOI – block metabolism of DA and NE
– TCA – block reuptake of NE and 5HT
8.
9. Neuroendocrine Factors
MDD-
- elevated cortisol levels
- no suppression of ACTH release in the dexamethasone
suppression test
- chronically elevated levels of corticotropin-releasing hormone
Abnormal thyroid function
11. Selective Serotonin Reuptake Inhibitors
• Inhibition of the serotonin transporter (SERT)
• Fluoxetine was introduced in the United States in 1988
• Fluoxetine
• Paroxetine
• Sertraline
• Citalopram
• Escitalopram
• Dapoxetine
15. Pharmacodynamics
• Extracellular serotonin Receptors on the transporter
Serotonin, Na and cl- Conformational change
• SSRIs allosterically inhibit the transporter
• At therapeutic doses, about 80% of the activity of the transporter is
inhibited
17. Side Effects of SSRIs
• Nausea , diarrhea and emesis (5HT3)
• Insomnia, increased anxiety, irritability, and decreased libido (5HT2)
• Paroxetine ---weight gain
18. SSRI Discontinuation Syndrome
*SSRIs should NOT be stopped Abruptly
• Dizziness, nausea, fatigue, headache, insomnia, restlessness, unstable
gait and shock like sensations (rare)
• More apparent with short acting SSRIs
(paroxetine > fluvoxamine > sertraline > citalopram >> fluoxetine)
19. Drug Interactions
Paroxetine and Fluoxetine CYP2D6 inhibitors
TCA
Fluvoxamine CYP3A4 inhibitor
Diltiazem
SSRIs + MAOI Serotonin syndrome
20. Advantages of SSRIs
• Ease of use
• Better tolerability
• Produce little /no sedation
• Do not interfere with psychomotor function
• No anticholinergic side effects
• No alpha adrenergic blocking action
• Do not inhibit cardiac function
26. Pharmacodynamics
• NET - 12-transmembrane domain complex that allosterically binds NE
• Venlafaxine is a weak inhibitor of NET
• Desvenlafaxine
• Duloxetine NET + SERT
• Milnacipran
• SNRIs lack – antihistamine, alpha adrenergic blocking and anticholinergic
effects of TCA
28. ADVERSE EFFECTS
• Nausea, constipation, insomnia, headaches, and sexual dysfunction.
• Immediate-release formulation of venlafaxine
sustained diastolic hypertension(10-15%)
• Duloxetine ----hepatotoxic
• Discontinuation syndrome
29. Drug Interactions
Duloxetine (moderate inhibitor of CYP2D6 )
Elevate TCA
• Milnacipran----------CYP3A4---------KETOCONAZOLE
SNRIs are contraindicated in combination with MAOIs
31. Other uses for TCAs
• Treatment of pain conditions
• Enuresis
• Insomnia
32.
33. MOA
• Antagonism of SERT and NET
• NET (desipramine, nortriptyline, protriptyline, amoxapine)
• SERT and NET (imipramine, amitriptyline, clomipramine ,doxepin)
• (H1 histamine, 5HT2, α1 adrenergic, and muscarinic cholinergic
receptors)
37. Adverse effects
• Anticholinergic effects
(dry mouth, constipation, urinary retention, blurred vision, and confusion)
• α-blocking property orthostatic hypotension
• H 1 antagonism by the TCAs is associated with weight gain and sedation
• The TCAs are class 1A antiarrhythmic agents and arrhythmogenic at higher
doses
43. Pharmacodynamics
• Nefazodone is a weak inhibitor of SERT and NET
Potent antagonist of the postsynaptic 5-HT 2A receptor
• Trazodone - selective inhibitor of SERT
+
- presynaptic α-adrenergic–blocking property
+
- modest antagonist of the H 1 receptor
45. Adverse Effects
• sedation and gastrointestinal disturbances
• Trazodone- can induce priapism
• orthostatic hypotension
• Hepatotoxicity (Nefazodone )
46. Drug Interactions
• Triazolam levels are increased by concurrent administration of
nefazodone
Nefazodone with simvastatin
20-fold increase in plasma levels of simvastatin
ritonavir or ketoconazole ------ increases in trazodone
47. Tetracyclic and Unicyclic Antidepressants
• Bupropion (unicyclic aminoketone structure)
• Mirtazapine
• Amoxapine tetracyclic chemical structure
• Maprotiline
• Vilazodone – multi ring structure .
48. Pharmacokinetics
• Bupropion - rapidly absorbed
- protein binding of 85%
- undergoes extensive hepatic metabolism
- Bupropion has a biphasic elimination
Amoxapine 7-hydroxyamoxapine(D2 blocker)
50. Pharmacodynamics
• Bupropion – moderate inhibitors of NE and 5-HT reuptake
- pre synaptic release of catecholamines
• Mirtazapine – antagonist of presynaptic alpha 2 auto receptor.
• Amoxapine and Maprotiline
Potent NET inhibitors
• Vilazodone is a potent serotonin reuptake inhibitor + partial agonist of 5 HT
1A receptor.
54. Monoamine oxidase inhibitors
• Mitochondrial enzyme involved in the oxidative deamination of
biogenic amines
• MAOA metabolizes 5HT ,NE and DA
• MAOB ------- 5HT and DA
• Rarely used
( toxicity and drug interactions )
62. Cheese reaction
Certain varieties of cheese,beer,wines,pickled meat, and fish
Large quantity of tyramine and dopa
MAOI ------indirect sympathomimetic stimulation
Hypertensive crisis, cerebrovascular accidents
63. Drug interaction
MAOI vs SSRIs/SNRIs/TCA
Serotonin syndrome
MAOI vs Tyramine
Malignant hypertension
Stroke/ myocardial infarction
67. 1. Major depression
• SSRI/SNRIs
• Trial therapy – 8-12 weeks at therapeutic dose
• Goal- remission of all the symptoms
• Inadequate response ----(SSRI +SNRI) + atypical antidepressants
• Long term maintenance needed -----2 or more serious MDD in the previous
5 years or 3 or more serious episodes in the life time .
75. Summary
• Pathophysiology
• Classification of antidepressants
• Pharmacokinetics and pharmacodynamics
• Adverse effects and drug interactions
• CYP enzymes and antidepressants
steroid -suppression of transcription of the BDNF gene
Cyclic AMP responsive binding protein
Fluoxetine, sertraline, and citalopram exist as isomers and are formulated in the racemic forms
Escitalopram is the S enantiomer of citalopram
Paroxetine and fluvoxamine are not optically active
fluoxetine and paroxetine are potent inhibitors of the CYP2D6
fluvoxamine is an inhibitor of CYP3A4
Fluoxetine to norfluoxetine
SERT is a glycoprotein with 12 transmembrane regions embedded in the axon terminal and cell body membranes of serotonergic neurons.
Agitation ,restlessness,rigidity,hyperthermia,delirium,twitching followed by convulsion
CYP2D6,CYP1A2
NET is structurally very similar to the 5-HT transporter
TRICYCLIC CORE
SEDATIVE EFFECT
SO NIGHT TIME DOSE
Therapuetic window ---50-200ng/ml imipramine,amitryptiline,nortryptiline
2 antagonist. Trazodone was among the most commonly prescribed antidepressants until it was supplanted by the SSRIs in the late 1980s……..unlabeled hypnotic
2A
n efazodone is an inhibitor of the CYP3A4 isoenzyme
Amoxapine is N –methylated metabolite of loxapine
with the first phase lasting about 1 hour and the second phase lasting 14 hours
MIRTAZAPINE ----NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT
Psychosis, excitation, confusion
Similar reaction can occur with ephedrine , SSRIs, SNRIs and levodopa